Investment analysts at Maxim Group initiated coverage on shares of Kyntra Bio (NASDAQ:KYNB – Get Free Report) in a research note issued to investors on Tuesday, MarketBeat reports. The firm set a “buy” rating and a $35.00 price target on the stock.
Several other analysts have also recently weighed in on KYNB. Lake Street Capital began coverage on Kyntra Bio in a report on Thursday, September 17th. They set a “buy” rating and a $41.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $43.00 price objective on shares of Kyntra Bio in a research note on Tuesday, September 1st. Weiss Ratings lowered shares of Kyntra Bio from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, October 9th. Finally, Oppenheimer initiated coverage on shares of Kyntra Bio in a report on Monday, July 6th. They issued an “outperform” rating and a $35.00 price objective for the company. Five investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $36.80.
Check Out Our Latest Stock Analysis on Kyntra Bio
Kyntra Bio Stock Down 5.1%
Institutional Trading of Kyntra Bio
A hedge fund recently bought a new stake in Kyntra Bio stock. ADAR1 Capital Management LLC purchased a new position in shares of Kyntra Bio Inc (NASDAQ:KYNB – Free Report) in the first quarter, according to its most recent filing with the SEC. The firm purchased 10,469 shares of the company’s stock, valued at approximately $71,000. ADAR1 Capital Management LLC owned 0.26% of Kyntra Bio at the end of the most recent quarter. 72.71% of the stock is owned by hedge funds and other institutional investors.
Kyntra Bio Company Profile
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
See Also
- Five stocks we like better than Kyntra Bio
- Tesla Wants to Make Its Own Chips—What Could Go Wrong?
- IREN Limited’s AI Pivot Gains Traction—But Can Its Data Centers Deliver?
- PBF Energy’s Stunning Rally Faces a Critical Test
- Citi Stock Falls Despite Earnings Beat: What Investors Need to Know
Receive News & Ratings for Kyntra Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kyntra Bio and related companies with MarketBeat.com's FREE daily email newsletter.
